Guska develops solutions based on synthetic RNA oncolytic virus therapy that have potent and safe immunostimulatory effects to address the pain point of cancer treatment by providing a targeted and less harmful alternative to traditional therapies. Our technology uses synthetic RNA viruses designed to safely reach and destroy cancer cells without affecting normal cells and promoting a robust immune response against tumor cells.
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.